Pfizer Has Proposed to “Vaccinate a Few Million Brazilians in First Semester 2021”

The company was the first to complete the last phase of trials and announced 95 percent efficacy. Immunizer use will be subject to ANVISA licensing.

RIO DE JANEIRO, BRAZIL - The American pharmaceutical company Pfizer and the German laboratory BioNTech said on Wednesday, November 18th, that they proposed the Brazilian government to commercialize the BNT162b2 vaccine against Covid-19.

In the morning, the companies announced the completion of trials and that the immunizer is 95 percent effective.

"Pfizer has made a proposal to the Brazilian government, in line with the agreements that we have closed with other countries - including Latin America, which would allow to vaccinate a few millions of Brazilians in the first semester, subject to regulatory approval," reported the company in a note.

The . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?